GlassScriptPhysician profile
Steven P Gorman
NPI 1104926500
$2,892.70
in general payments reported to CMS, 2019-2025
28 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $519 · 2021: $638 · 2022: $219 · 2023: $397 · 2024: $293 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $967 · Education: $16.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $966.52 |
| Education | $16.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $391.53 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.73 | 2019-2025 | Jardiance |
| Abbvie INC. | $313.14 | 2021-2025 | |
| Daiichi Sankyo INC. | $254.36 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $220.65 | 2019-2021 | |
| Pfizer INC. | $194.04 | 2019-2021 | |
| Novo Nordisk INC | $187.87 | 2021-2025 | Wegovy |
| Amgen INC. | $145.88 | 2021-2024 | Krystexxa |
| Vertex Pharmaceuticals Incorporated | $123.49 | 2025 | |
| Sanofi Pasteur INC. | $106.00 | 2019 | |
| Lilly USA, LLC | $89.96 | 2019-2023 | Emgality, Jardiance |
| Exact Sciences Corporation | $66.75 | 2023-2024 | Cologuard Collection Kit |
| Eisai INC. | $65.69 | 2021 | |
| Amarin Pharma, INC. | $58.97 | 2020-2021 | |
| Almatica Pharma LLC | $53.40 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $50.71 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $35.57 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $31.06 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $30.90 | 2024 | Opsumit |
| Philips North America LLC | $22.38 | 2019 | |
| Boston Scientific Corporation | $19.16 | 2023 | Watchman Flx |
| Orexo US, INC. | $17.53 | 2021 | |
| Tactile Systems Technology INC | $16.57 | 2022 | |
| Agios Pharmaceuticals, INC. | $16.53 | 2024 | Pyrukynd |
| Astellas Pharma US INC | $16.26 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.37 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.16 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Gorman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.